“…It is noteworthy to mention that aberrant activation of Wnt signaling pathways is obviously not limited to the four cancer types mentioned below. Various Wnt ligands, the agonist Norrin, Fz receptors and the co-receptors Lrp6 and Ror1/2 have been reported to be abnormally expressed and associated with metastatic behavior, cancer progression and chemoresistance in ovarian cancer, glioblastoma multiforme, chronic lymphocytic leukemia, melanoma, multiple myeloma, post-transplant smooth muscle tumor, prostate cancer, pancreatic cancer gastric cancer, oral squamous cell carcinoma, Ewing sarcoma, osteosarcoma, and malignant peripheral nerve sheath tumors ( Derksen et al, 2004 ; Larue and Delmas, 2006 ; Dissanayake et al, 2007 ; Yan et al, 2016 ; Yu et al, 2016 ; Li et al, 2017 , 2019a ; Liu et al, 2017 ; Pridgeon et al, 2017 ; Sandsmark et al, 2017 ; Jiang et al, 2018 ; Sinnberg et al, 2018 ; Teiken et al, 2018 ; Yang et al, 2019b ; Chehover et al, 2020 ; El-Sehemy et al, 2020 ; Frenquelli et al, 2020 ; Kotrbova et al, 2020 ). Thus, a thorough understanding of misregulation of Wnt signaling pathways at the plasma membrane will pave the way for new therapeutic approaches for cancer.…”